PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33142664-5 2020 As a hydrophilic nucleoside analogue, gemcitabine requires nucleoside transporters to permeate the plasma membrane, and a major role in the uptake of this drug is played by human equilibrative nucleoside transporter 1 (hENT-1). Nucleosides 17-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-217 31752123-3 2019 Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). Nucleosides 78-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 32126230-9 2020 Of these, hENT1 and hENT2 transport both nucleosides and nucleobases into and out of cells, but their relative contributions to nucleoside and nucleobase homeostasis and, in particular, to adenosine signaling via purinoreceptors, are not known. Nucleosides 41-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 32126230-9 2020 Of these, hENT1 and hENT2 transport both nucleosides and nucleobases into and out of cells, but their relative contributions to nucleoside and nucleobase homeostasis and, in particular, to adenosine signaling via purinoreceptors, are not known. Nucleosides 41-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 32428837-1 2020 Nucleoside analogs are subject to resistance mechanisms including downregulation of equilibrative nucleoside transporter (ENT1) and deoxycytidine kinase (dCK). Nucleosides 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 122-126 31601121-11 2019 Higher hENT1 expression in MDA-MB231 seems to drive nucleoside transport, whereas TK1 expression in MCF7 seems responsible for comparable [18F]FLT retention in ER+ tumors. Nucleosides 52-62 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 7-12 31551431-0 2019 Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1. Nucleosides 120-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-100 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Nucleosides 151-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Nucleosides 151-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 31235912-6 2019 Our studies provide a platform for improved pharmacological intervention of adenosine and nucleoside analog drug transport by hENT1. Nucleosides 90-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 126-131 30528800-1 2019 Human equilibrative nucleoside transporter 1 (hENT-1) is a membrane nucleoside transporter mediating the intracellular uptake of nucleosides and their analogues. Nucleosides 129-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 30528800-1 2019 Human equilibrative nucleoside transporter 1 (hENT-1) is a membrane nucleoside transporter mediating the intracellular uptake of nucleosides and their analogues. Nucleosides 129-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-52 30254099-1 2018 Human equilibrative nucleoside transporter 1 (hENT1), the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for cellular uptake of physiologic nucleosides and many antineoplastic and antiviral nucleoside drugs. Nucleosides 191-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 30469356-7 2018 Overall, these data suggest that HepaRG cells may be useful for analyzing cellular pharmacokinetics of nucleoside-like drugs in human hepatic cells, especially of those handled by ENT1. Nucleosides 103-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 180-184 30254099-1 2018 Human equilibrative nucleoside transporter 1 (hENT1), the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for cellular uptake of physiologic nucleosides and many antineoplastic and antiviral nucleoside drugs. Nucleosides 191-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 30254099-1 2018 Human equilibrative nucleoside transporter 1 (hENT1), the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for cellular uptake of physiologic nucleosides and many antineoplastic and antiviral nucleoside drugs. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 29530865-6 2018 Transport analyses of hENT3-hENT1 chimeric constructs demonstrated that the N-terminal half of hENT3 is primarily responsible for the hENT3-3"-deoxy-nucleoside analog interaction. Nucleosides 149-159 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-33 30143259-1 2018 Human equilibrative nucleoside transporter 1 (hENT1) transports nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-tumor drugs. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 29864673-3 2018 This activation occurred within hours after addition of the nucleosides and was primarily dependent on the ENT1 nucleoside transporter protein. Nucleosides 60-71 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 107-111 28254415-1 2017 The human equilibrative nucleoside transporter-1 (hENT1) is important for the entry of anti-cancer and anti-viral nucleoside analog therapeutics into the cell, and thus for their efficacy. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 28729424-2 2017 Unlike the prototypic human ENT members hENT1 and hENT2, which mediate plasma membrane nucleoside transport at pH 7.4, hENT3 is an acidic pH-activated lysosomal transporter partially localized to mitochondria. Nucleosides 87-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 28254415-2 2017 Understanding of hENT1 structure-function relationship could assist with development of nucleoside analogs with better cellular uptake properties. Nucleosides 88-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 17-22 27009875-4 2016 Calcium-dependent human ENT1-CaM protein interactions were confirmed in human cell lines (HEK293, RT4, U-87 MG) using biochemical assays (HEK293) and the functional assays (HEK293, RT4), which confirmed modified nucleoside uptake that occurred in the presence of pharmacological manipulations of calcium levels and CaM function. Nucleosides 212-222 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-28 28417642-3 2017 In vitro expression levels of equilibrative nucleoside transporter 1 (ENT1) has been shown to be a predictor of treatment response in patients receiving nucleoside-based chemotherapeutic agents. Nucleosides 44-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-74 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Nucleosides 106-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Nucleosides 86-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 28218790-1 2017 Human equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC). Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-78 27906634-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) is a major route of entry of nucleosides and nucleoside analog drugs. Nucleosides 82-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 27906634-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) is a major route of entry of nucleosides and nucleoside analog drugs. Nucleosides 82-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27906634-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) is a major route of entry of nucleosides and nucleoside analog drugs. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27422302-1 2016 PURPOSE: The solute carrier family 29 (equilibrative nucleoside transporter), member 1 (SLC29A1) is known to be involved in the transportation and resistance of the nucleoside analog cytosine arabinoside (AraC), one of the most effective drugs in the treatment of acute myeloid leukemia (AML). Nucleosides 53-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 27480168-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) transports nucleosides and nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-cancer, anti-parasitic and anti-viral drugs. Nucleosides 64-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 27480168-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) transports nucleosides and nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-cancer, anti-parasitic and anti-viral drugs. Nucleosides 64-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27480168-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) transports nucleosides and nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-cancer, anti-parasitic and anti-viral drugs. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27009875-7 2016 These data support the existence of a previously unidentified novel receptor-dependent regulatory mechanism, whereby intracellular calcium modulates nucleoside and NA drug uptake via CaM-dependent interaction of ENT1. Nucleosides 149-159 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 212-216 26688730-2 2015 In beta-thalassemia major, where hemoglobin instability imposes oxidative stress, erythrocytes show reduced hENT1 nucleoside transporter expression and decreased nucleoside uptake. Nucleosides 114-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-113 26162242-1 2015 Human equilibrative nucleoside transporter-1 (hENT1) is the major plasma membrane transporter involved in transportation of natural nucleosides as well as nucleoside analog drugs, used in anti-cancer and anti-viral therapies. Nucleosides 132-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 26162242-1 2015 Human equilibrative nucleoside transporter-1 (hENT1) is the major plasma membrane transporter involved in transportation of natural nucleosides as well as nucleoside analog drugs, used in anti-cancer and anti-viral therapies. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Nucleosides 128-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-46 25896650-3 2015 The resulting p.Glu391Lys variation in the last extracellular loop of the equilibrative nucleoside transporter 1 (ENT1; also called SLC29a1) is known not to alter its ability to transport nucleosides and nucleoside analog drugs. Nucleosides 188-199 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-112 25896650-3 2015 The resulting p.Glu391Lys variation in the last extracellular loop of the equilibrative nucleoside transporter 1 (ENT1; also called SLC29a1) is known not to alter its ability to transport nucleosides and nucleoside analog drugs. Nucleosides 88-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 25896650-3 2015 The resulting p.Glu391Lys variation in the last extracellular loop of the equilibrative nucleoside transporter 1 (ENT1; also called SLC29a1) is known not to alter its ability to transport nucleosides and nucleoside analog drugs. Nucleosides 88-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 132-139 26070128-7 2015 ENT1 inhibitors may also affect the cellular transport, and hence the efficacy, of anticancer and antiviral nucleoside analogs used in chemotherapy. Nucleosides 108-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Nucleosides 128-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Nucleosides 14-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 24976360-5 2014 Both cell types displayed similar transporter expression profiles, with the majority (>90%) of 2-chloro[(3)H]adenosine (nucleoside) uptake mediated by ENT1 and [(3)H]hypoxanthine (nucleobase) uptake mediated by ENBT1. Nucleosides 123-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 25713072-8 2015 siRNA knockdown experiments demonstrate that the nucleoside transporter, hENT1, plays a key role in the cellular entry of Ir(III)-PPY nucleoside. Nucleosides 49-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 73-78 25713533-5 2015 SLC29 genes encode four members, being hENT1 and hENT2 the only two which are unequivocally implicated in the translocation of nucleosides and nucleobases (the latter mostly via hENT2) at the cell plasma membrane. Nucleosides 127-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 25519698-9 2015 In clinical settings, TKI inhibitor concentrations in tumor tissues are sufficient to inhibit hENT1 activity, thereby reducing nucleoside chemotherapy drug levels in cancer cells and reducing efficacy in combination schedules. Nucleosides 127-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-99 24788480-2 2014 Given the role of hENT1 in the transport of nucleoside drugs, an important class of therapeutics in the treatment of various cancers and viral infections, efforts have been made to better understand the mechanisms by which hENT1 modulates nucleoside transport. Nucleosides 44-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 24788480-2 2014 Given the role of hENT1 in the transport of nucleoside drugs, an important class of therapeutics in the treatment of various cancers and viral infections, efforts have been made to better understand the mechanisms by which hENT1 modulates nucleoside transport. Nucleosides 44-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 223-228 24788480-2 2014 Given the role of hENT1 in the transport of nucleoside drugs, an important class of therapeutics in the treatment of various cancers and viral infections, efforts have been made to better understand the mechanisms by which hENT1 modulates nucleoside transport. Nucleosides 239-249 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 223-228 24163005-0 2014 The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity. Nucleosides 175-185 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-31 24163005-7 2014 These data suggest that the presence of ethanol may compromise ENT1-dependent nucleoside analog drug cytotoxicity, and indeed, ethanol (5 mM) reduces the cytotoxic effects of gemcitabine (2 nM), an anti-cancer drug, in the human cancer cell line, HTB2. Nucleosides 78-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-67 24522200-1 2014 Human equilibrative nucleoside transporter 1 (hENT1) transports various nucleoside analogues into cells. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 24163005-1 2014 The adenosine transporter 1 (ENT1) transports nucleosides, such as adenosine, and cytotoxic nucleoside analog drugs. Nucleosides 46-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-33 24163005-1 2014 The adenosine transporter 1 (ENT1) transports nucleosides, such as adenosine, and cytotoxic nucleoside analog drugs. Nucleosides 46-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-33 22349506-1 2012 Human equilibrative nucleoside transporter 1 (hENT1) is an important determinant for nucleoside analog based chemotherapy success. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 22644860-1 2012 The concentrative nucleoside transporter CNT1 and equilibrated nucleoside transporter ENT1 mediate the cellular uptake of naturally occurring pyrimidine and purine nucleosides and many structurally diverse anticancer and antiviral nucleoside analogs, thereby regulating drug responses or toxicity at the target site. Nucleosides 164-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-90 22985987-2 2012 ENT1 facilitates transport of FLT into cells and elevated levels of FLT are associated with both larger FLT-PET signals and increased response to nucleoside-based chemotherapies. Nucleosides 146-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 21382338-7 2011 No alterations of the deoxynucleotide pools were found, whereas a reduction in the expression of genes involved in nucleoside/nucleotide homeostasis (human equilibrative nucleoside transporter 1, thymidine phosphorylase) and mtDNA maintenance (DNA-polymerase gamma, mitochondrial transcription factor A) was observed. Nucleosides 115-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-194 21809900-2 2011 ENT1 is expressed ubiquitously in mammalian tissues and responsible for a significant portion of nucleoside analog drug uptake in humans. Nucleosides 97-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 21402067-3 2011 hENT1 is responsible for the uptake of nucleoside analog drugs used in treating viral infections and cancer, but despite its clinical importance, virtually nothing is known about the dynamics of the hENT1 life cycle including trafficking to the PM, endocytosis and degradation. Nucleosides 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 19699178-1 2009 Human Equilibrative Nucleoside Transporter 1 (hENT1) is an integral membrane protein that transports nucleosides and analog drugs across cellular membranes. Nucleosides 101-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 21443122-1 2010 BACKGROUND/AIMS: Human Equilibrative Nucleoside Transporters 1 (hENT1) gene is involving in mediating nucleosides and nucleoside analog drugs across the plasma membrane, and may affect the chemotherapeutical efficacy. Nucleosides 102-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 21443122-1 2010 BACKGROUND/AIMS: Human Equilibrative Nucleoside Transporters 1 (hENT1) gene is involving in mediating nucleosides and nucleoside analog drugs across the plasma membrane, and may affect the chemotherapeutical efficacy. Nucleosides 102-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 19699178-1 2009 Human Equilibrative Nucleoside Transporter 1 (hENT1) is an integral membrane protein that transports nucleosides and analog drugs across cellular membranes. Nucleosides 101-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 19244331-10 2009 Interestingly, some RBV-resistant cell lines may compensate for reduced ENT1-mediated nucleoside uptake by increasing the activity of an alternative nucleoside transporter, ENT2. Nucleosides 86-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-76 19116148-6 2009 These results define G24 as critical amino acid for ENT1 nucleoside uptake and suggest that mutations in TM1 may provide a mechanism for Ara-C resistance in CCRF-CEM Ara-C/8C cells. Nucleosides 57-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-56 18589402-4 2008 Overexpression of hENT1 is associated with changes in cell cycle profile, in a variable manner depending on the particular cell type, thus suggesting a metabolic link between hENT1-mediated transport processes and the enzymatic machinery responsible for intracellular nucleoside metabolism. Nucleosides 268-278 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 18589402-4 2008 Overexpression of hENT1 is associated with changes in cell cycle profile, in a variable manner depending on the particular cell type, thus suggesting a metabolic link between hENT1-mediated transport processes and the enzymatic machinery responsible for intracellular nucleoside metabolism. Nucleosides 268-278 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-180 18589402-6 2008 In summary, hENT1 overexpression is associated with alterations in nucleoside enzymatic machinery and cell cycle progression in cultured cells and enhances gemcitabine action in vivo. Nucleosides 67-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-17 18078872-4 2008 The aim of this study was to investigate whether IL-4 is able to modulate the expression and function of the human equilibrative NT1 (hENT1) in primary cultures of CLL cells and, consequently, to affect cytotoxicity induced by therapeutic nucleosides analogs. Nucleosides 239-250 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 134-139 17215872-5 2006 The well characterized hENTs (hENT1 and hENT2) are bidirectional facilitative diffusion transporters in plasma membranes; hENT3 and hENT4 are much less well known, although hENT3, found in lysosomal membranes, transports nucleosides and is pH dependent, whereas hENT4-PMAT is a H+-adenosine cotransporter as well as a monoamine-organic cation transporter. Nucleosides 221-232 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-35 16965766-0 2006 Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5"-DFUR in breast cancer MCF7 cells. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. Nucleosides 257-267 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. Nucleosides 257-267 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 17215872-7 2006 In renal epithelial cells, hCNT1, hCNT2, and hCNT3 at apical membranes, and hENT1 and hENT2 at basolateral membranes, apparently work in concert to mediate reabsorption of nucleosides from lumen to blood, driven by Na+ gradients. Nucleosides 172-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 17215872-9 2006 Mounting evidence suggests that hENT1 may have a presence at both apical and basolateral membranes of renal epithelia, and thus may participate in both selective secretory and reabsorptive fluxes of nucleosides. Nucleosides 199-210 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-37 16085043-1 2005 Human equilibrative, Na(+)-independent nucleoside transport is mediated by membrane proteins sensitive (system es, hENT1) or insensitive (system ei, hENT2) to nitrobenzylthioinosine (NBMPR). Nucleosides 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 115-120 16818276-9 2006 INTERPRETATION AND CONCLUSIONS: These results further support the concept that nucleoside transporters are implicated in the therapeutic response to nucleoside analogs, and suggest a particular and novel role for hENT1 in the genotoxic response to selected nucleoside analogs, such as gemcitabine, in MCL cells. Nucleosides 79-89 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 213-218 16818276-9 2006 INTERPRETATION AND CONCLUSIONS: These results further support the concept that nucleoside transporters are implicated in the therapeutic response to nucleoside analogs, and suggest a particular and novel role for hENT1 in the genotoxic response to selected nucleoside analogs, such as gemcitabine, in MCL cells. Nucleosides 149-159 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 213-218 16617163-5 2006 The apparent affinities of recombinant transporters (produced in yeast) for a panel of cytosine-containing nucleosides yielded results that were consistent with the observed low-permeant activities of TaraC and araC for hENT1/2 and negligible permeant activities for hCNT1/2/3. Nucleosides 107-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 220-227 15529184-3 2005 Since some nucleoside analogs have a role in treating patients with non-Hodgkin"s lymphoma (NHL), this study was undertaken to assess hENT1 abundance in NHL. Nucleosides 11-21 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 134-139 15529184-12 2005 Prospective studies to assess the value of hENT1 immunostaining in predicting resistance to nucleoside chemotherapy for NHL are warranted. Nucleosides 92-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 15644498-1 2005 Human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) differ functionally in that hENT2 generally displays lower affinity for its nucleoside permeants and is less sensitive to inhibition by the coronary vasodilators dilazep and dipyridamole. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-58 15037197-0 2004 Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Nucleosides 33-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 15571274-1 2004 The uptake of nucleosides and nucleoside analogs into human leukemia K562 cells is facilitated by the equilibrative transporters ENT1 and ENT2. Nucleosides 14-25 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 14978234-3 2004 To define the relative and unified structural requirements of nucleoside analogs for interaction with hCNT1, hCNT2, and hENT1, we applied an array of structure-activity techniques. Nucleosides 62-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-125 15649894-8 2005 This study demonstrated that the corresponding residues in TMs 1 and 11 of hENT1, hENT2, and CeENT1 are important for dipyridamole interactions and nucleoside transport. Nucleosides 148-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-80 15571274-1 2004 The uptake of nucleosides and nucleoside analogs into human leukemia K562 cells is facilitated by the equilibrative transporters ENT1 and ENT2. Nucleosides 14-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 15371014-3 2004 These transporters resemble their human counterparts hENT1 and hENT2 in exhibiting similar broad permeant specificities for nucleosides, while differing in their permeant selectivities for nucleobases. Nucleosides 124-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-58 15205344-5 2004 We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. Nucleosides 55-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-53 15205344-5 2004 We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. Nucleosides 55-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-82 15037197-2 2004 hENT1 is ubiquitously expressed and plays an important role in the disposition and pharmacological activity of nucleoside drugs and nucleosides, such as adenosine. Nucleosides 111-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-2 2004 hENT1 is ubiquitously expressed and plays an important role in the disposition and pharmacological activity of nucleoside drugs and nucleosides, such as adenosine. Nucleosides 132-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-4 2004 hENT1 and hENT2 differ in their affinity for nucleoside substrates and in their sensitivity to inhibitors, such as nitrobenzylthioinosine (NBMPR). Nucleosides 45-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-5 2004 hENT1 has higher (or equal) affinity to hENT2 for all natural nucleosides except inosine. Nucleosides 62-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 114-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 306-310 15043160-1 2004 The sugar moiety of nucleosides has been shown to play a major role in permeant-transporter interaction with human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2). Nucleosides 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 115-160 15043160-1 2004 The sugar moiety of nucleosides has been shown to play a major role in permeant-transporter interaction with human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2). Nucleosides 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 162-167 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 114-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 317-324 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 250-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 306-310 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 250-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 317-324 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 250-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 306-310 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 250-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 317-324 12724623-1 2003 The human equilibrative nucleoside transporter, ENT1, appears to play a critical role in the disposition of nucleosides and nucleoside analogs used clinically as anti-viral and anti-cancer drugs. Nucleosides 108-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 12527552-11 2003 These data suggest that hENT1 and hENT2 on the basolateral membrane function with concentrative nucleoside transporters on the apical membrane to mediate active reabsorption of nucleosides within the kidney. Nucleosides 177-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-29 12724623-1 2003 The human equilibrative nucleoside transporter, ENT1, appears to play a critical role in the disposition of nucleosides and nucleoside analogs used clinically as anti-viral and anti-cancer drugs. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 12389626-11 2002 We conclude that, because hENT1 deficiency has been previously related to nucleoside-drug resistance, immunohistochemical staining for hENT1 warrants evaluation as a predictive tool for guiding the appropriate use of gemcitabine in the treatment of HD. Nucleosides 74-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-31 12590919-1 2003 Protein glycosylation is important for nucleoside transport, and this has been demonstrated for the human equilibrative nucleoside transporter-1 (hENT1). Nucleosides 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 106-144 12590919-1 2003 Protein glycosylation is important for nucleoside transport, and this has been demonstrated for the human equilibrative nucleoside transporter-1 (hENT1). Nucleosides 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 12069239-1 2002 The human equilibrative nucleoside transporter 1 protein (hENT1) is a major mediator of cellular entry of nucleosides and anticancer nucleoside drugs; its assay is important in understanding and diagnosing chemotherapy resistance. Nucleosides 106-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 12069239-1 2002 The human equilibrative nucleoside transporter 1 protein (hENT1) is a major mediator of cellular entry of nucleosides and anticancer nucleoside drugs; its assay is important in understanding and diagnosing chemotherapy resistance. Nucleosides 106-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 12069239-1 2002 The human equilibrative nucleoside transporter 1 protein (hENT1) is a major mediator of cellular entry of nucleosides and anticancer nucleoside drugs; its assay is important in understanding and diagnosing chemotherapy resistance. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 11584005-1 2001 The human equilibrative nucleoside transporter hENT1, the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for the cellular uptake of physiologic nucleosides, including adenosine, and many anti-cancer nucleoside drugs. Nucleosides 195-206 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 11814344-0 2002 A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Nucleosides 47-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 11814344-2 2002 hENT1 is involved in the uptake of natural nucleosides, including regulation of the physiological effects of extracellular adenosine, and transports nucleoside drugs used in the treatment of cancer and viral diseases. Nucleosides 43-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 11814344-3 2002 Structure-function studies have revealed that transmembrane domains (TMD) 3 through 6 of hENT1 may be involved in binding of nucleosides. Nucleosides 125-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-94 11584005-1 2001 The human equilibrative nucleoside transporter hENT1, the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for the cellular uptake of physiologic nucleosides, including adenosine, and many anti-cancer nucleoside drugs. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 9804860-9 1998 These results provided evidence for the presence of functional es and ei transporters in nuclear membranes and endoplasmic reticulum, suggesting that hENT1 and hENT2 may function in the translocation of nucleosides between the cytosol and the luminal compartments of one or both of these membrane types. Nucleosides 203-214 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-155 9353301-3 1997 When expressed in Xenopus oocytes, hENT1 mediated es-type transport activity and was inhibited by coronary vasoactive drugs (dipyridamole and dilazep) that may compete with nucleosides and NBMPR for binding to the substrate binding site. Nucleosides 173-184 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 34275128-1 2021 BACKGROUND AND OBJECTIVES: Equilibrative nucleoside transporter (ENT) 1 is a widely-expressed drug transporter, handling nucleoside analogues as well as endogenous nucleosides. Nucleosides 121-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-71 34275128-1 2021 BACKGROUND AND OBJECTIVES: Equilibrative nucleoside transporter (ENT) 1 is a widely-expressed drug transporter, handling nucleoside analogues as well as endogenous nucleosides. Nucleosides 164-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-71 34275128-11 2021 This point likely merits attention in terms of possible drug-drug interactions, notably for nucleoside analogues, whose ENT1-mediated uptake into their target cells may be hampered by co-administrated TKIs such as lorlatinib. Nucleosides 92-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-124 35221865-13 2022 Nucleoside transporters, such as ENT1, are vital in the uptake of synthetic nucleoside analogue drugs, used in cancer and viral chemotherapy. Nucleosides 76-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-37 11311901-6 2001 The apparent reciprocal distribution of hENT1 and hENT2 in human brain suggests that these nucleoside transporter proteins are produced in distinct regions of the CNS where they function in nucleoside salvage and/or regulation of exogenous adenosine. Nucleosides 91-101 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 11396612-4 2001 Whilst the name of the family reflects the properties of its prototypical member hENT1, an equilibrative transporter of nucleosides, some family members can also transport nucleobases and some are proton-dependent, concentrative transporters. Nucleosides 120-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 34382915-3 2021 In the present study, we discovered that RNA-derived modified nucleosides are exported to extracellular space through equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), with ENT1 showing higher preference for modified nucleosides than ENT2. Nucleosides 62-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 165-169 34382915-3 2021 In the present study, we discovered that RNA-derived modified nucleosides are exported to extracellular space through equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), with ENT1 showing higher preference for modified nucleosides than ENT2. Nucleosides 62-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 186-190 34382915-3 2021 In the present study, we discovered that RNA-derived modified nucleosides are exported to extracellular space through equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), with ENT1 showing higher preference for modified nucleosides than ENT2. Nucleosides 230-241 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 165-169 34382915-3 2021 In the present study, we discovered that RNA-derived modified nucleosides are exported to extracellular space through equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), with ENT1 showing higher preference for modified nucleosides than ENT2. Nucleosides 230-241 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 186-190 34382915-4 2021 Pharmacological inhibition or genetic deletion of ENT1 and ENT2 significantly attenuated export of modified nucleosides thereby resulting in their accumulation in cytosol. Nucleosides 108-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-54 34382915-5 2021 Using mutagenesis strategy, we identified an amino acid residue in ENT1 that is involved in the discrimination of unmodified and modified nucleosides. Nucleosides 138-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71